Literature DB >> 25443611

Cardio-embolic stroke due to valve tissue embolization during percutaneous transseptal mitral commissurotomy (PTMC).

Sudhir S Shetkar1, Neeraj Parakh2, Birdevender Singh1, N K Mishra3, Ruma Ray4, Ganesan Karthikeyan1, Rakesh Yadav1, Kewal C Goswami1.   

Abstract

Percutaneous transseptal mitral commissurotomy (PTMC) has replaced surgical commissurotomy as a treatment of choice in selected patients of rheumatic mitral stenosis. Various randomized trials have shown PTMC to be equal or superior to surgical commissurotomy in terms of hemodynamic improvement as well as long term survival. Systemic embolism is one of the dreaded complications of PTMC, which is reported in 0.5-5% of cases and involves cerebral circulation in 1% of cases. Most of the time, periprocedural embolism during PTMC is caused by the mobilization of preexisting thrombus in the left atrial appendage. We report an unusual case of acute stroke due embolization of mitral valve tissue during PTMC.
Copyright © 2014 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Embolization; Mitral stenosis; Stroke; Valve tissue

Mesh:

Year:  2014        PMID: 25443611      PMCID: PMC4223213          DOI: 10.1016/j.ihj.2014.05.022

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


  9 in total

Review 1.  Percutaneous approaches to valvular disease.

Authors:  Alec Vahanian; Igor F Palacios
Journal:  Circulation       Date:  2004-04-06       Impact factor: 29.690

2.  Calcium embolism of the coronary arteries after percutaneous mitral balloon valvuloplasty.

Authors:  B D Powell; D R Holmes; R A Nishimura; C S Rihal
Journal:  Mayo Clin Proc       Date:  2001-07       Impact factor: 7.616

Review 3.  Percutaneous balloon mitral valvuloplasty: a review.

Authors:  Masakiyo Nobuyoshi; Takeshi Arita; Shin-ichi Shirai; Naoya Hamasaki; Hiroyoshi Yokoi; Masashi Iwabuchi; Hitoshi Yasumoto; Hideyuki Nosaka
Journal:  Circulation       Date:  2008-12-23       Impact factor: 29.690

4.  Systemic embolism as a complication of percutaneous mitral valvuloplasty.

Authors:  G Drobinski; G Montalescot; J Evans; M Nivet; D Thomas; Y Grosgogeat
Journal:  Cathet Cardiovasc Diagn       Date:  1992-04

5.  Percutaneous balloon versus surgical closed and open mitral commissurotomy: seven-year follow-up results of a randomized trial.

Authors:  M Ben Farhat; M Ayari; F Maatouk; F Betbout; H Gamra; M Jarra; M Tiss; S Hammami; R Thaalbi; F Addad
Journal:  Circulation       Date:  1998-01-27       Impact factor: 29.690

6.  Transesophageal echocardiography to detect atrial clots in candidates for percutaneous transseptal mitral balloon valvuloplasty.

Authors:  I Kronzon; P A Tunick; E Glassman; J Slater; M Schwinger; R S Freedberg
Journal:  J Am Coll Cardiol       Date:  1990-11       Impact factor: 24.094

Review 7.  Current status of endovascular stroke treatment.

Authors:  Philip M Meyers; H Christian Schumacher; E Sander Connolly; Eric J Heyer; William A Gray; Randall T Higashida
Journal:  Circulation       Date:  2011-06-07       Impact factor: 29.690

8.  Comparison of long-term results of percutaneous mitral balloon valvotomy with closed transventricular mitral commissurotomy at a single North American Institution.

Authors:  S R Ommen; R A Nishimura; D E Grill; D R Holmes; C S Rihal
Journal:  Am J Cardiol       Date:  1999-09-01       Impact factor: 2.778

Review 9.  [Peripheral calcific embolism after percutaneous mitral valvuloplasty].

Authors:  G Montalescot; G Drobinski; D Thomas; O Bletry; A Delcourt; J Evans; R Isnard; E Kieffer; Y Grosgogeat
Journal:  Arch Mal Coeur Vaiss       Date:  1992-06
  9 in total
  1 in total

1.  Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations.

Authors:  Kaavya Narasimhalu; Yoong Kwei Ang; Doreen Su Yin Tan; Deidre Anne De Silva; Kelvin Bryan Tan
Journal:  Clin Drug Investig       Date:  2020-11       Impact factor: 2.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.